Trevi Therapeutics’ (TRVI) Buy Rating Reiterated at HC Wainwright

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $21.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 76.77% from the company’s current price.

Several other research firms have also recently commented on TRVI. Oppenheimer raised their price target on Trevi Therapeutics from $23.00 to $24.00 and gave the company an “outperform” rating in a report on Friday, November 14th. D. Boral Capital reiterated a “buy” rating and issued a $19.00 price objective on shares of Trevi Therapeutics in a research report on Thursday, January 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Wednesday, January 21st. Stifel Nicolaus boosted their target price on shares of Trevi Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Finally, B. Riley Financial upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a report on Monday, November 17th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $21.10.

Trevi Therapeutics Stock Down 10.7%

NASDAQ TRVI traded down $1.42 during trading hours on Monday, hitting $11.88. 1,033,596 shares of the stock were exchanged, compared to its average volume of 1,406,810. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -32.11 and a beta of 0.94. Trevi Therapeutics has a 12-month low of $4.85 and a 12-month high of $14.39. The stock has a 50-day moving average of $11.26 and a 200 day moving average of $10.73.

Hedge Funds Weigh In On Trevi Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. grew its holdings in shares of Trevi Therapeutics by 194.5% during the second quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock worth $25,000 after buying an additional 2,996 shares in the last quarter. Hilton Head Capital Partners LLC purchased a new position in shares of Trevi Therapeutics during the fourth quarter valued at approximately $40,000. Caitong International Asset Management Co. Ltd acquired a new stake in Trevi Therapeutics during the fourth quarter worth approximately $50,000. Strs Ohio purchased a new stake in Trevi Therapeutics in the 1st quarter worth approximately $52,000. Finally, Catalyst Funds Management Pty Ltd purchased a new stake in Trevi Therapeutics in the 2nd quarter worth approximately $56,000. 95.76% of the stock is owned by institutional investors and hedge funds.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.